Collaboration with SRI International

On July 10, 2017, Thermo Fisher Scientific (TMO) announced its collaboration with SRI International to enable researchers to carry out more effective and efficient small molecule research and analysis based on mass spectrometry. The collaboration should help to accelerate TMO’s mass spectrometry business.

The collaboration should provide researchers with the combination of the high-resolution Orbitrap liquid chromatography and mass spectrometry experiments’ results from TMO’s Compound Discoverer 2.1 software platform and the organism-specific metabolic pathway and genome data from SRI International’s BioCyc database.

TMO’s Recent Developments in the Small Molecule Research Field

The Orbitrap franchise is already an established product technology in the market, and the collaboration will further strengthen TMO’s Life Sciences Solutions business and help it to expand its presence in the space.

SRI International is a California-based independent research company. The company was founded at Stanford University as Stanford Research Institute, and it separated from the university in 1970. SRI International provides client-sponsored research to various commercial and government organizations.

Other major companies in the US medical device industry, including Medtronic (MDT), Becton, Dickinson and Company (BDX), and Abbott Laboratories (ABT), have also adopted strategic collaborations and partnerships as major strategies for the growth and expansion of their existing businesses. In this way, they provide their customers with more comprehensive and efficient product offerings.

Investors interested in gaining exposure to Thermo Fisher Scientific and its peers can consider the Vanguard Health Care ETF (VHT), which holds ~2.0% in TMO.

Management’s comments

According to Andreas Hummer, Thermo Fisher’s director of proteomics and metabolomics marketing, chromatography, and mass spectrometry, “Today, metabolomics researchers can measure thousands of small molecules, but it can be challenging to know which cellular systems are behaving differently in the studied condition compared to a control.”

Hummer continued, “The new integration will allow scientists using Compound Discoverer to automatically map the most detected compounds to BioCyc metabolic pathway diagrams and to connect additional experimental data, such as relative abundance or differential expression, onto the pathways.”

Latest articles

Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.

The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.

Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.

Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.

14 Jun

IEA Again Slashes Its Oil Demand Growth Estimate

WRITTEN BY Rabindra Samanta

As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.

14 Jun

Why Kimberly-Clark Stock May Stop Rising


Kimberly-Clark (KMB) stock has risen 20.5% this year, boosted by the company’s better-than-expected sales and earnings during its last reported quarter. However, its stock could stop climbing. Here's why.